39937 Investors following Ranbaxy Labs. Share this News with them.
0
Like this story, share it with millions of investors on M3
No pill for Ranbaxy's pain!
Ranbaxy was a stock that cracked in trade today as details of the consent decree by US Justice Department were made public and turned out more stringent than expected.
Ranbaxy was a stock that cracked in trade today as details of the consent decree by US Justice Department were made public and turned out more stringent than expected.
Along with a comprehensive correction and audit roadmap, the decree also forfeits a 180-day marketing exclusivity for three of Ranbaxy's products, which were not named, reports CNBC-TV18's Archana Shukla.
A lot is at risk for Ranbaxy. The biggest hit in the near-term for Ranbaxy is the loss of 180-day marketing exclusivity for three of its products.
There are other five opportunities that are also under threat, if the company doesn't submit proper details to USFDA within a stipulated timeframe.
Besides that, in the next three months, the company also has to set out other product data compliances to the USFDA. If the company fails, they may also withdraw some of their potential ANDA filings from the US market.
